Only 3% of US sickle cell patients receive red blood cell exchange for disease, researchers find

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-27 • Permanent link

Severe weather conditions brought widespread destruction to the northeastern United States on Sunday, leaving nearly 100,000 households without power. The National Weather Service reported that gusts of up to 80 miles per hour battered the area, causing extensive damage to homes, businesses, and infrastructure. Thousands of residents were left stranded, with many forced to seek shelter in nearby towns. The Federal Emergency Management Agency (FEMA) has been deployed to assist with relief efforts.

The devastating impact of the storm on the US economy is already being felt, with many experts predicting a significant increase in costs for insurers and property owners. The National Insurance Crime Bureau estimates that the total damage from the storm could exceed $10 billion, with many of those costs likely to be passed on to consumers through higher insurance premiums. The storm is also expected to have a significant impact on the US stock market, with many analysts predicting a decline in the Dow Jones index.

Since the early 2000s, the development of red blood cell exchange treatments for sickle cell patients has been a topic of interest for researchers and industry experts. The treatment, which involves replacing the patient's red blood cells with healthy ones, has been shown to be highly effective in reducing the severity of the disease. However, despite its benefits, the treatment remains underutilized, with many patients unable to access it due to a lack of availability and high costs.

What drove this shortage of red blood cell exchange treatments is a complex issue, with many factors contributing to the lack of access for sickle cell patients. The high cost of the treatment, combined with a lack of insurance coverage and limited availability, has made it difficult for many patients to access the treatment. Researchers are now working to develop more affordable and accessible treatments, which could help to improve outcomes for sickle cell patients and reduce the economic burden of the disease.